奥拉巴里布新陈代谢:量子化学,对接和基于动力学的洞察力,对机制和反应性的洞察力
Anila Nuthi1, Upadhyayula Suryanarayana Murty1, Vaibhav A Dixit1
1Department of Medicinal Chemistry, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, National Institute of Pharmaceutical Education and Research, Guwahati, (NIPER Guwahati) Govt. of India, Sila Katamur (Halugurisuk), Changsari, Kamrup, 781101 Guwahati, Assam, India.
通过CYP450 3A4/5的Olaparib代谢产生有毒的代谢产物. 计算研究表明,由M6形成的反应性M12代谢物具有高度的电友性,这解释了olaparib的存在.
科学领域:
- 药用化学 医学化学
- 计算化学计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 一种抗癌药物Olaparib具有主要的副作用,如肝毒性和血液毒性.
- 人类CYP450 3A4/5将olaparib代谢成脱 (M11) 和化 (M6,M15) 代谢产物.
- 主要代谢物M11是无反应的,使olaparib毒性的原因无法解释.
研究的目的:
- 使用计算模型研究olaparib的代谢途径.
- 识别潜在的反应性代谢物,并了解它们在olaparib诱导的毒性中所起的作用.
- 为了了解代谢偏好,并指导设计更安全的olaparib类似物.
主要方法:
- 量子化学计算,包括潜在能量表面 (PES) 分析与激活和反应自由能量.
- 分子对接和动力学模拟以评估代谢部位的可访问性.
- 密度函数理论 (DFT) 用于全球和局部反应性分析 (电友性).
主要成果:
- 脱化 (M11) 和化 (M6) 代谢物形成比M15.
- 主要代谢物M11通过一种涉及脱水的E1机制形成.
- 由M6衍生出的活性M12代谢物具有高度电友性的4-乙甲-1(2H) - 一组,这可能解释了毒性.
结论:
- 电友性M12代谢物的形成与olaparib的特异性毒性有关.
- 已经阐明了代谢偏好和反应性代谢物形成途径.
- 这些发现为设计新型,毒性较低的olaparib类似物提供了基础.
更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
05:51Isotopic Effect in Double Proton Transfer Process of Porphycene Investigated by Enhanced QM/MM Method
Published on: July 19, 2019
相关概念视频
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Quantitative Aspects of Drug-Receptor Interaction
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Drug Metabolism: Phase I Reactions
The Equilibrium Binding Constant and Binding Strength
